Therapeutic Response

ER positive and PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.

Statements

Source and description
Letrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.
Letrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.
Letrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior adjuvant treatment for 5 years.
Femara (letrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor positive invasive early breast cancer.
Femara (letrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior standard adjuvant tamoxifen therapy for 5 years.
Femara (letrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the first-line treatment of patients who are postmenopausal women with hormone-dependent advanced breast cancer.